BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36379302)

  • 1. A method for early diagnosis of lung cancer from tumor originated DNA fragments using plasma cfDNA methylome and fragmentome profiles.
    Kim YJ; Jeon H; Jeon S; Lee SH; Kim C; Ahn JH; Um H; Woo YJ; Jeong SH; Kim Y; Park HY; Oh HJ; Cho HJ; Bae JH; Kim JH; An S; Kang SB; Jho S; Biro O; Kis D; Kim BC; Kim Y; Kim JH; Kim BC; Bhak J; Oh IJ
    Mol Cell Probes; 2022 Dec; 66():101873. PubMed ID: 36379302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-time analysis of the cancer genome and fragmentome from plasma and urine cell-free DNA using nanopore sequencing.
    van der Pol Y; Tantyo NA; Evander N; Hentschel AE; Wever BM; Ramaker J; Bootsma S; Fransen MF; Lenos KJ; Vermeulen L; Schneiders FL; Bahce I; Nieuwenhuijzen JA; Steenbergen RD; Pegtel DM; Moldovan N; Mouliere F
    EMBO Mol Med; 2023 Dec; 15(12):e17282. PubMed ID: 37942753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
    Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
    Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization.
    Bie F; Wang Z; Li Y; Guo W; Hong Y; Han T; Lv F; Yang S; Li S; Li X; Nie P; Xu S; Zang R; Zhang M; Song P; Feng F; Duan J; Bai G; Li Y; Huai Q; Zhou B; Huang YS; Chen W; Tan F; Gao S
    Nat Commun; 2023 Sep; 14(1):6042. PubMed ID: 37758728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients.
    Janke F; Angeles AK; Riediger AL; Bauer S; Reck M; Stenzinger A; Schneider MA; Muley T; Thomas M; Christopoulos P; Sültmann H
    Clin Epigenetics; 2022 Dec; 14(1):163. PubMed ID: 36461127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.
    Liu L; Toung JM; Jassowicz AF; Vijayaraghavan R; Kang H; Zhang R; Kruglyak KM; Huang HJ; Hinoue T; Shen H; Salathia NS; Hong DS; Naing A; Subbiah V; Piha-Paul SA; Bibikova M; Granger G; Barnes B; Shen R; Gutekunst K; Fu S; Tsimberidou AM; Lu C; Eng C; Moulder SL; Kopetz ES; Amaria RN; Meric-Bernstam F; Laird PW; Fan JB; Janku F
    Ann Oncol; 2018 Jun; 29(6):1445-1453. PubMed ID: 29635542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidimensional fragmentomic profiling of cell-free DNA released from patient-derived organoids.
    Kim J; Hong SP; Lee S; Lee W; Lee D; Kim R; Park YJ; Moon S; Park K; Cha B; Kim JI
    Hum Genomics; 2023 Oct; 17(1):96. PubMed ID: 37898819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating cell-free DNA sequencing for early detection of lung cancer.
    Xue R; Yang L; Yang M; Xue F; Li L; Liu M; Ren Y; Qi Y; Zhao J
    Expert Rev Mol Diagn; 2023; 23(7):589-606. PubMed ID: 37318381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-free DNA methylation in the clinical management of lung cancer.
    Ezegbogu M; Wilkinson E; Reid G; Rodger EJ; Brockway B; Russell-Camp T; Kumar R; Chatterjee A
    Trends Mol Med; 2024 May; 30(5):499-515. PubMed ID: 38582623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
    Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
    Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
    Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylome profiling identifies TCHH methylation in CfDNA as a noninvasive marker of liver metastasis in colorectal cancer.
    Chen S; Liu T; Bu D; Zhu J; Wang X; Pan Y; Liu Y; Lu ZJ; Wang P
    FASEB J; 2021 Jul; 35(7):e21720. PubMed ID: 34110642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic analysis of cell-free DNA by fragmentomic profiling.
    Zhou Q; Kang G; Jiang P; Qiao R; Lam WKJ; Yu SCY; Ma ML; Ji L; Cheng SH; Gai W; Peng W; Shang H; Chan RWY; Chan SL; Wong GLH; Hiraki LT; Volpi S; Wong VWS; Wong J; Chiu RWK; Chan KCA; Lo YMD
    Proc Natl Acad Sci U S A; 2022 Nov; 119(44):e2209852119. PubMed ID: 36288287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum circulating free DNA of syncytin-1 as a novel molecular marker for early diagnosis of non-small-cell lung cancer.
    Zhuang X; Qian J; Xia X; Wang Y; Wang H; Jing L; Zhang Y; Zhang Y
    Biomark Med; 2022 Dec; 16(18):1259-1268. PubMed ID: 36861469
    [No Abstract]   [Full Text] [Related]  

  • 16. cfDNA methylome profiling for detection and subtyping of small cell lung cancers.
    Chemi F; Pearce SP; Clipson A; Hill SM; Conway AM; Richardson SA; Kamieniecka K; Caeser R; White DJ; Mohan S; Foy V; Simpson KL; Galvin M; Frese KK; Priest L; Egger J; Kerr A; Massion PP; Poirier JT; Brady G; Blackhall F; Rothwell DG; Rudin CM; Dive C
    Nat Cancer; 2022 Oct; 3(10):1260-1270. PubMed ID: 35941262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer.
    Wang S; Meng F; Li M; Bao H; Chen X; Zhu M; Liu R; Xu X; Yang S; Wu X; Shao Y; Xu L; Yin R
    Am J Respir Crit Care Med; 2023 May; 207(9):1203-1213. PubMed ID: 36346614
    [No Abstract]   [Full Text] [Related]  

  • 18. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of methylation status using WGS data of plasma cfDNA for multi-cancer early detection (MCED).
    Cui P; Zhou X; Xu S; He W; Huang G; Xiong Y; Zhang C; Chang T; Feng M; Lai H; Pan Y
    Clin Epigenetics; 2024 Feb; 16(1):34. PubMed ID: 38414068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Universal lung epithelium DNA methylation markers for detection of lung damage in liquid biopsies.
    Magenheim J; Rokach A; Peretz A; Loyfer N; Cann G; Amini H; Moradi P; Nagaraju S; Sameer W; Cohen A; Fogel O; Kuint R; Abutbul A; Abu Rmeileh A; Karameh M; Cohen Goichman P; Wald O; Korach A; Neiman D; Fox-Fisher I; Moss J; Cohen D; Piyanzin S; Ben Ami R; Quteineh A; Golomb E; Shemer R; Glaser B; Kaplan T; Fridlender ZG; Dor Y
    Eur Respir J; 2022 Nov; 60(5):. PubMed ID: 35450968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.